Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual disease (MRD) monitoring, due to the availability of drug combinations capable of unprecedented complete clinical responses. The standardized and most commonly applied methods to assess MRD in CLL are based on fl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: Del Giudice, Ilaria, Raponi, Sara, Della Starza, Irene, De Propris, Maria Stefania, Cavalli, Marzia, De Novi, Lucia Anna, Cappelli, Luca Vincenzo, Ilari, Caterina, Cafforio, Luciana, Guarini, Anna, Foà, Robin
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727319/
https://ncbi.nlm.nih.gov/pubmed/31555576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00689
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares